Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Invion ( (AU:IVX) ) has shared an announcement.
Invion Limited has issued 11,318,060 fully paid ordinary shares following the maturity of 72,024 unlisted convertible notes, confirming that the issuance was conducted without a prospectus under relevant Corporations Act provisions and that it remains compliant with its continuous disclosure and reporting obligations. The company also disclosed ongoing discussions with potential contract research organisations, capital providers and third parties about expanding its clinical trial and research program into additional indications and exploring non-human applications for its compounds, while stressing that no binding agreements have yet been reached and that there is no certainty any transactions will proceed.
The most recent analyst rating on (AU:IVX) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Invion stock, see the AU:IVX Stock Forecast page.
More about Invion
Invion Limited is an ASX-listed life-science company focused on developing Photosoft technology, a next-generation photodynamic therapy for treating a range of cancers. The company holds the Australia and New Zealand licence rights to Photosoft, with research and clinical trials funded by licensor RMW Cho Group and its affiliates under an R&D services agreement.
Average Trading Volume: 122,258
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.68M
For an in-depth examination of IVX stock, go to TipRanks’ Overview page.